Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG2077 in Systemic Lupus Erythematosus
NCT00094380Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2004
- Primary completion
- Jan 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of RG2077 in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2004; status: completed.
02
Drugs
RG2077
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT00094380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094380.